Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

Not a serious argument, given the sudden Covid pandemic onset and Brilacidin's stellar research thus far.

Just imagine the outcry if Leo had not diverted resources from the potential $500M market for B-OM, and pivoted to go head to head with the EUA remdesivir drug, for a portion of the multi-Billion dollar Covid pandemic market.

Leo's flexibility may be the saving grace for this company, but if B for C-19 strikes out in the current clinical trial now nearing full enrollment, then and only then will your argument hold.

More likely Brilacidin will show its therapeutic power, and there will be subsequent B licensing agreements for IBD indications as well as OM.